Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...